Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue

Cancer Research

Volumn 60, Issue 3, 2000, Pages 666-671

  Sawa, Tomohiro ^a   Wu, Jun ^a   Akaike, Takaaki ^a   Maeda, Hiroshi ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROGEN PEROXIDE; HYPOXANTHINE; MACROGOL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; XANTHINE OXIDASE;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG TARGETING; GROWTH INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; FREE RADICALS; HEME OXYGENASE (DECYCLIZING); INJECTIONS, INTRAVENOUS; MALE; MICE; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; REACTIVE OXYGEN SPECIES; TISSUE DISTRIBUTION; XANTHINE OXIDASE;

EID: 0033965528     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Fridovich, I. Quantitative aspects of the production of superoxide anion radical by milk xanthine oxidase. J. Biol. Chem., 245: 4053-4057, 1970.
2. Haddow, A., De Lamirande, G., Bergel, F., Bray, R. C., and Gilbert, D. A. Anti-tumor and biochemical effects of purified bovine xanthine oxidase in C3H and C mice. Nature (Lond.), 182: 1144-1146, 1958.
3. Yoshikawa, T., Kokura, S., Tainaka, K., Naito, Y., and Kondo, M. A novel cancer therapy based on oxygen radicals. Cancer Res., 55, 1617-1620, 1995.
4. Bray, R. C., and Swann, J. C., Moribudenum-containing enzymes. Struct. Bonding, 11: 107-144, 1972.
5. Yen, H. C., Oberley, T. D., Vichitbandha, S., Ho, Y. S., and St. Clair, D. K. The protective role of manganese superoxide dismutase against Adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Investig., 98: 1253-1260, 1996.
6. Adachi, T., Fukushima, T., Usami, Y., and Hirano, K. Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. Biochem. J., 289: 523-527, 1993.
7. Radi, R., Rubbo, H., Bush, K., and Freeman, B. A. Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interaction of immobilized xanthine oxidase-heparin complexes. Arch. Biochem. Biophys., 339: 125-135, 1997.
8. Houston, M., Estevez, A., Chumley, P., Asian, M., Marklund, S., Parks, D. A., and Freeman, B. A. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J. Biol. Chem., 274: 4985-4994, 1999.
9. Moncada, S., Palmer, R. M., and Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43: 109-142, 1991.
10. Nakazono, K., Watanabe, N., Matsuno, K., Sasaki, J., Sato, T., and Inoue, M. Does superoxide underlie the pathogenesis of hypertension? Proc. Natl. Acad. Sci. USA, 88: 10045-10048, 1991.
11. Bruder, G., Jarasch, E-D., and Heid, H. W. High concentrations of antibodies to xanthine oxidase in human and animal sera: molecular characterization. J. Clin. Investig., 74: 783-794, 1984.
12. Ng, Y. L., and Lewis, W. H. Circulating immune complexes of xanthine oxidase in normal subjects. Br. J. Biomed. Sci., 51: 124-127, 1994.
13. Matsumura, Y., and Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res., 46: 6387-6392, 1986.
14. Maeda, H., and Kojima, Y. Polymer-drug conjugates. In: R. Arshady (ed.), Desk Reference of Functional Polymers: Synthesis and Application, pp. 753-767. Washington, DC: American Chemical Society, 1997.
15. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Delivery Rev., 6: 181-202, 1991.
16. Maeda, H., and Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst., 6: 193-210, 1989.
17. Li, C. J., Miyamoto, Y., Kojima, Y., and Maeda, H. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer, 67: 975-980, 1993.
18. Iwai, K., Maeda, H., and Konno, T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res., 44: 2115-2121, 1984.
19. Iwai, K., Maeda, H., Konno, T., Matsumura, Y., Yamashita, R., Yamasaki, K., Hirayama, S., and Miyauchi, Y. Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res., 7: 321-328, 1987.
20. Seymour, L. W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J. Ulbrich, K., and Duncan, R. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer, 31: 766-770, 1995.
21. Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., and Maeda, H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res., 89: 307-314, 1998.
22. Wu, J., Akaike, T., and Maeda, H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res., 58: 159-165, 1998.
23. Konno, T., Maeda, H., Iwai, K., Maki, S., Tashiro, S., Uchida, M., and Miyauchi, Y. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer (Phila.), 54: 2367-2374, 1984.
24. Seymour, L. W., Olliff, S. P., Poole, C. J., De Takats, P. G., Orme, R., Ferry, D. R., Maeda, H., Konno, T., and Kerr, D. J. A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate)-neocarzinostatin] in the treatment of primary hepatocellular carcinoma. Int. J. Oncol., 12: 1217-1223, 1998.
25. Muggia, F. M. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin. Cancer Res., 5: 7-8, 1999.
26. Vasey, P. A., Kaye, S. B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., Burtles, S., Fraier, D., Frigerio, E., and Cassidy, J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res., 5: 83-94, 1999.
27. Fields, R. The rapid determination of amino groups with TNBS. Methods Enzymol., 25:464-468, 1972.
28. Hunt, J., and Massey, V. Purification and properties of milk xanthine dehydrogenase. J. Biol. Chem., 267: 21479-21485, 1992.
29. 2 generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J. Clin. Investig., 85: 739-745, 1990.
30. Maeda, H., Kimura, M., Sasaki, I., Hirose, Y., and Konno, T. Toxicity of bilirubin and detoxification by PEG-bilirubin oxidase conjugate: a new tactic for treatment of jaundice. In: J. M. Harris (ed.), Polyethylene glycol) Chemistry: Biotechnical and Biomedical Applications, pp. 153-169. New York: Plenum Publishing Corp., 1992.
31. Abuchowski, A., van Es, T., Palczuk, N. C., and Davis, F. F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem., 252, 3578-3581, 1977.
32. Wada, H., Imamura, I., Sako, M., Katagiri, S., Tarui, S., Nishimura, H., and Inada, Y. Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann. NY Acad. Sci., 613: 95-108, 1990.
33. Halliwell, B., and Gutteridge, J. M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J., 219: 1-14, 1984.
34. Harris, J. M. Introduction to biotechnical and biomedical applications of poly(ethylene glycol). In: J. M. Harris (ed.). Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications, pp. 1-14. New York: Plenum Publishing Corp., 1992.
35. 2: improved stability of SOD in vitro and in vivo. J. Bioactive Compatible Polymers, 11: 169-190, 1996.
36. Maeda, H., Noguchi, Y., Sato, K., and Akaike, T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res., 85: 331-334, 1994.
37. Maeda, H., Akaike, T., Wu, J., Noguchi, Y., and Sakata, Y. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology, 33: 222-230, 1996.
38. Doi, K., Akaike, T., Horie, H., Noguchi, Y., Fujii, S., Beppu, T., Ogawa, M., and Maeda, H. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer (Phila.), 77: 1598-1604, 1996.
39. Matsumura, Y., Maeda, H., and Kato, H. Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC. Agents Actions, 29: 172-180, 1990.
40. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington DC), 219: 983-985, 1983.
41. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
42. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
43. Ohtani, H., and Sasano, N. Microvascular changes in the stroma of human colorectal carcinomas: ultrastructural histochemical study. Jpn. J. Cancer Res., 80: 360-365, 1989.
44. Suzuki, M., Takahashi, T., and Sato, T. Medial regression and its functional significance in tumor-supplying host arteries. A morphometric study of hepatic arteries in human livers with hepatocellular carcinoma. Cancer (Phila.), 56: 444-450, 1987.
45. Maeda, H., Ueda, M., Morinaga, T., and Matsumoto, T. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J. Med. Chem., 28: 455-461, 1985.
46. Konno, T., Maeda, H., Iwai, K., Tashiro, S., Maki, S., Morinaga, T., Mochinaga, M., Hiraoka, T., and Yokoyama, I. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur. J. Cancer Clin. Oncol., 19: 1053-1065, 1983.
47. Sun, Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radical Biol. Med., 8: 583-599, 1990.
48. Sato, K., Ito, K., Kohara, H., Yamaguchi, Y., Adachi, K., and Endo, H. Negative regulation of catalase gene expression in hepatoma cells. Mol. Cell. Biol., 12: 2525-2533, 1992.
49. Krinick, N. L., Sun, Y., Joyner, D., Spikes, J. D., Straight, R. C., and Kopecek, J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomater. Sci. Polym. Ed., 5: 303-324, 1994.
50. Tabata, Y., Murakami, Y., and Ikada, Y. Photodynamic effect of polyethylene glycol-modified fullerene on tumor. Jpn. J. Cancer Res., 88: 1108-1116, 1997.
51. Pryor, W. A., and Squadrito, G. L. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am. J. Physiol., 268: L699-L722, 1995.
52. Szabo, C., and Ohshima, H. DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide, 1: 373-385, 1997.
53. Doi, K., Akaike, T., Fujii, S., Tanaka, S., Ikebe, N., Beppu, T., Shibahara, S., Ogawa, M., and Maeda, H. Induction of heme oxygenase-1 by nitric oxide and ischemia in experimental solid tumors and implications for tumor growth. Br. J. Cancer, 80: 1945-1954, 1999.